Literature DB >> 28077274

The role and regulation of the peroxisome proliferator activated receptor alpha in human liver.

Sander Kersten1, Rinke Stienstra2.   

Abstract

The peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that is abundantly expressed in liver. PPARα is activated by fatty acids and various other lipid species, as well as by a class of chemicals referred to as peroxisome proliferators. Studies in mice have shown that PPARα serves as the master regulator of hepatic lipid metabolism during fasting. In addition, PPARα suppresses inflammation and the acute phase response. Comparatively little is known about PPARα in human liver. Here, an overview is provided of the role and regulation of PPARα in human liver. The main outcomes are: 1) the level of PPARA mRNA expression in human and mouse liver is similar. 2) Expression of PPARA in human liver is reduced in patients with non-alcoholic steatohepatitis or infected with the hepatitis C virus. 3) PPARα in human liver is able to effectively induce the expression of numerous genes involved in numerous lipid metabolic pathways, including microsomal, peroxisomal and mitochondrial fatty acid oxidation, fatty acid binding and activation, fatty acid elongation and desaturation, synthesis and breakdown of triglycerides and lipid droplets, lipoprotein metabolism, gluconeogenesis, bile acid metabolism, and various other metabolic pathways and genes. 4) PPARα activation in human liver causes the down-regulation of a large number of genes involved in various immunity-related pathways. 5) Peroxisome proliferators do not promote tumour formation in human liver as opposed to mouse liver because of structural and functional differences between human and mouse PPARα. 6) In addition to helping to correct dyslipidemia, PPARα agonists may hold promise as a therapy for patients with cholestatic liver diseases, non-alcoholic fatty liver disease, and/or type 2 diabetes.
Copyright © 2017 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Human liver; Lipid metabolism; Non-alcoholic fatty liver disease; PPARα; Target genes

Mesh:

Substances:

Year:  2017        PMID: 28077274     DOI: 10.1016/j.biochi.2016.12.019

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  77 in total

1.  Host genetics and gut microbiota cooperatively contribute to azoxymethane-induced acute toxicity in Collaborative Cross mice.

Authors:  Chenhan Zhong; Li He; Sun-Young Lee; Hang Chang; Yuqing Zhang; David W Threadgill; Ying Yuan; Fuling Zhou; Susan E Celniker; Yankai Xia; Antoine M Snijders; Jian-Hua Mao
Journal:  Arch Toxicol       Date:  2021-01-17       Impact factor: 5.153

2.  Molecular fingerprint of female bovine embryos produced in vitro with high competence to establish and maintain pregnancy†.

Authors:  A M Zolini; J Block; M B Rabaglino; P Tríbulo; M Hoelker; G Rincon; J J Bromfield; P J Hansen
Journal:  Biol Reprod       Date:  2020-02-14       Impact factor: 4.285

3.  Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21.

Authors:  Mohammad Zarei; Eugènia Pujol; Tania Quesada-López; Francesc Villarroya; Emma Barroso; Santiago Vázquez; Javier Pizarro-Delgado; Xavier Palomer; Manuel Vázquez-Carrera
Journal:  Br J Pharmacol       Date:  2019-05-23       Impact factor: 8.739

4.  Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.

Authors:  Rebecca L Scalzo; Deirdre Rafferty; Irene Schauer; Amy G Huebschmann; Melanie Cree-Green; Jane E B Reusch; Judith G Regensteiner
Journal:  J Diabetes Complications       Date:  2019-05-10       Impact factor: 2.852

5.  Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice.

Authors:  Chad N Brocker; Daxesh P Patel; Thomas J Velenosi; Donghwan Kim; Tingting Yan; Jiang Yue; Guolin Li; Kristopher W Krausz; Frank J Gonzalez
Journal:  J Lipid Res       Date:  2018-08-29       Impact factor: 5.922

6.  Role of peroxisome proliferator-activated receptor-α on the synthesis of monounsaturated fatty acids in goat mammary epithelial cells.

Authors:  Huibin Tian; Jun Luo; Hengbo Shi; Xiaoying Chen; Jiao Wu; Yusheng Liang; Cong Li; Juan J Loor
Journal:  J Anim Sci       Date:  2020-03-01       Impact factor: 3.159

Review 7.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

8.  The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia.

Authors:  Sudeep Gautam; Lisa Zhang; Irina Arnaoutova; Cheol Lee; Brian C Mansfield; Janice Y Chou
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

9.  Intervention of Ayurvedic drug Tinospora cordifolia attenuates the metabolic alterations in hypertriglyceridemia: a pilot clinical trial.

Authors:  Amey Shirolkar; Aarti Yadav; T K Mandal; Rajesh Dabur
Journal:  J Diabetes Metab Disord       Date:  2020-10-16

Review 10.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.